Open AccessPositive effect of if-channel’s blocker ivabradine therapy in a patient with ischemic chronic heart failure with preserved left ventricle ejection fraction and hereditary thrombophilia (clinical case)
Author(s) -
Юрий Никитич Беленков,
Беленков Юрий Никитич,
Е. В. Привалова,
Привалова Елена Витальевна,
I. S. Ilgisonis,
Ильгисонис Ирина Сергеевна,
Iuliia I. Naymann,
Найманн Юлия Игоревна,
A. V. Zhito,
Жито Алексей Владимирович
Publication year - 2019
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/22217185.2019.3.190544
Subject(s) - ivabradine , medicine , heart failure , ejection fraction , cardiology , ventricle , bisoprolol , heart rate , blood pressure
Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermediate and final outcomes. According to the neurohumoral theory of chronic heart failure development, an antagonism of the sympathoadrenal system with b-blockers is pathogenetically substantiated, and the drugs of this group are one of the first-line treatment for chronic heart failure. The selection of heart rate-reducing therapy in patients with chronic heart failure caused by ischemia, can often be difficult due to development of b-blockers side effects, b-blockers intolerance and/or due to the presence of contraindications at severe comorbid pathology. This article presents a clinical case of an effective administration of ivabradine, a drug of if-channel inhibitors group, in combination with b-blockers to a patient with chronic heart failure with a preserved ejection fraction.